Company: OCEA
Filing Date: 2025-01-13
Form Type: 10-Q
Source: 0001493152-25-001880
Chunk: 210

Company: Ocean Biomedical, Inc.
Filing Date: 2025-01-13
Form: 10-Q
Item: Item 2
Chunk 210
---
ROs”) and contract manufacturing organizations (“CMOs”), and other drug development experts
    and consultants.

    ●
    Building a diverse portfolio
    of product candidates. We are evidence-based and program agnostic, meaning that our resources are driven strictly by program
    progress and milestone achievements. Our approach is to develop multiple diverse programs in parallel which mitigates business risk.

    ●
    Providing attractive
    economic upside to our partners at research universities and medical centers. We have a structure wherein our parent company
    houses each program in a subsidiary. We believe this structure is optimal to provide attractive economic incentives to the discovering
    institution and its researchers.

    ●
    Employing a multi-disciplinary
    approach to drug discovery and development across our programs. Our business model is based on bringing together the appropriate
    disciplines and expertise needed for each of our programs and leveraging learnings across programs and disease areas.

    ●
    Exploiting multiple
    commercialization options to maximize each program’s value. Throughout the development of our product candidates, we plan
    to continually assess that program’s potential paths to market, and we will endeavor to identify and maximize commercial value
    through various options, including internal advancement, partnerships with established companies, and spin-outs or other strategic
    transactions.

    ●
    Leadership team comprised
    of academic, scientific and business innovators. We have assembled an industry-leading, multi-disciplinary team consisting of
    physicians, scientists and business leaders with significant experience in progressing product candidates from early-stage research
    through clinical trials, regulatory approval and ultimately to commercialization. Although our company has not yet developed or commercialized
    any biopharmaceutical products, key members of our management team have experience doing so in previous endeavors.

We
believe our differentiated business model will enable us to commercialize our products, if approved, and will allow us to replicate our
licensing partnerships through aligned incentive structures with research universities and medical centers.

Our
pipeline consists of clinical-stage programs. We anticipate moving certain preclinical product candidates in our oncology, fibrosis and/or
infectious disease programs into the clinic in the next 12 to 24 months.

Since
Legacy Ocean’s inception in 2019, we have devoted substantially all of our efforts to organizing, research and development activities,
business planning, building our intellectual property positions and providing general and administrative support for these operations.
We have not generated any revenue from product sales.

We
have incurred significant operating losses since